Immunovant's fair value estimate is 19% higher than its analyst price target. Using a Discounted Cash Flow model, the intrinsic value of the company is calculated at US$8.5b, showing a 46% discount to the current share price.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing